Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors

Anthony T C Chan, Qian Tao, Keith D Robertson, Ian W. Flinn, Risa B. Mann, Barbara Klencke, Wing Hong Kwan, Thomas Wai Tong Leung, Philip J. Johnson, Richard F. Ambinder

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Purpose: To determine whether therapy with a DNA methyltransferase inhibitor is effective in achieving demethylation and gene re-expression in tumor DNA in patients. Methods: Biopsy specimens were obtained from patients with Epstein-Barr virus-associated tumors, enrolled on a clinical trial of 5-azacitidine, within 72 hours of the conclusion of the last infusion of the first cycle of therapy, and compared to pretreatment specimens. Methylation-specific polymerase chain reaction, bisulfite genomic sequencing, and immunohistochemistry were used to assess demethylation and gene re-expression. Results: Substantial degrees of demethylation were detected in all latent and lytic Epstein-Barr virus promoters examined. Immunohistochemistry suggested activation of a previously silent viral antigen expression in one instance. Conclusion: Pharmacologic reversal of dense CpG methylation in tumor tissue can be achieved in patients.

Original languageEnglish (US)
Pages (from-to)1373-1381
Number of pages9
JournalJournal of Clinical Oncology
Volume22
Issue number8
DOIs
StatePublished - 2004
Externally publishedYes

Fingerprint

Azacitidine
Human Herpesvirus 4
Genome
Methylation
Immunohistochemistry
Gene Expression
Neoplasms
Viral Antigens
DNA
Methyltransferases
Clinical Trials
Biopsy
Polymerase Chain Reaction
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chan, A. T. C., Tao, Q., Robertson, K. D., Flinn, I. W., Mann, R. B., Klencke, B., ... Ambinder, R. F. (2004). Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors. Journal of Clinical Oncology, 22(8), 1373-1381. https://doi.org/10.1200/JCO.2004.04.185

Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors. / Chan, Anthony T C; Tao, Qian; Robertson, Keith D; Flinn, Ian W.; Mann, Risa B.; Klencke, Barbara; Kwan, Wing Hong; Leung, Thomas Wai Tong; Johnson, Philip J.; Ambinder, Richard F.

In: Journal of Clinical Oncology, Vol. 22, No. 8, 2004, p. 1373-1381.

Research output: Contribution to journalArticle

Chan, ATC, Tao, Q, Robertson, KD, Flinn, IW, Mann, RB, Klencke, B, Kwan, WH, Leung, TWT, Johnson, PJ & Ambinder, RF 2004, 'Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors', Journal of Clinical Oncology, vol. 22, no. 8, pp. 1373-1381. https://doi.org/10.1200/JCO.2004.04.185
Chan, Anthony T C ; Tao, Qian ; Robertson, Keith D ; Flinn, Ian W. ; Mann, Risa B. ; Klencke, Barbara ; Kwan, Wing Hong ; Leung, Thomas Wai Tong ; Johnson, Philip J. ; Ambinder, Richard F. / Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors. In: Journal of Clinical Oncology. 2004 ; Vol. 22, No. 8. pp. 1373-1381.
@article{94a8dde9605142d1b9f739b6b88a9885,
title = "Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors",
abstract = "Purpose: To determine whether therapy with a DNA methyltransferase inhibitor is effective in achieving demethylation and gene re-expression in tumor DNA in patients. Methods: Biopsy specimens were obtained from patients with Epstein-Barr virus-associated tumors, enrolled on a clinical trial of 5-azacitidine, within 72 hours of the conclusion of the last infusion of the first cycle of therapy, and compared to pretreatment specimens. Methylation-specific polymerase chain reaction, bisulfite genomic sequencing, and immunohistochemistry were used to assess demethylation and gene re-expression. Results: Substantial degrees of demethylation were detected in all latent and lytic Epstein-Barr virus promoters examined. Immunohistochemistry suggested activation of a previously silent viral antigen expression in one instance. Conclusion: Pharmacologic reversal of dense CpG methylation in tumor tissue can be achieved in patients.",
author = "Chan, {Anthony T C} and Qian Tao and Robertson, {Keith D} and Flinn, {Ian W.} and Mann, {Risa B.} and Barbara Klencke and Kwan, {Wing Hong} and Leung, {Thomas Wai Tong} and Johnson, {Philip J.} and Ambinder, {Richard F.}",
year = "2004",
doi = "10.1200/JCO.2004.04.185",
language = "English (US)",
volume = "22",
pages = "1373--1381",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors

AU - Chan, Anthony T C

AU - Tao, Qian

AU - Robertson, Keith D

AU - Flinn, Ian W.

AU - Mann, Risa B.

AU - Klencke, Barbara

AU - Kwan, Wing Hong

AU - Leung, Thomas Wai Tong

AU - Johnson, Philip J.

AU - Ambinder, Richard F.

PY - 2004

Y1 - 2004

N2 - Purpose: To determine whether therapy with a DNA methyltransferase inhibitor is effective in achieving demethylation and gene re-expression in tumor DNA in patients. Methods: Biopsy specimens were obtained from patients with Epstein-Barr virus-associated tumors, enrolled on a clinical trial of 5-azacitidine, within 72 hours of the conclusion of the last infusion of the first cycle of therapy, and compared to pretreatment specimens. Methylation-specific polymerase chain reaction, bisulfite genomic sequencing, and immunohistochemistry were used to assess demethylation and gene re-expression. Results: Substantial degrees of demethylation were detected in all latent and lytic Epstein-Barr virus promoters examined. Immunohistochemistry suggested activation of a previously silent viral antigen expression in one instance. Conclusion: Pharmacologic reversal of dense CpG methylation in tumor tissue can be achieved in patients.

AB - Purpose: To determine whether therapy with a DNA methyltransferase inhibitor is effective in achieving demethylation and gene re-expression in tumor DNA in patients. Methods: Biopsy specimens were obtained from patients with Epstein-Barr virus-associated tumors, enrolled on a clinical trial of 5-azacitidine, within 72 hours of the conclusion of the last infusion of the first cycle of therapy, and compared to pretreatment specimens. Methylation-specific polymerase chain reaction, bisulfite genomic sequencing, and immunohistochemistry were used to assess demethylation and gene re-expression. Results: Substantial degrees of demethylation were detected in all latent and lytic Epstein-Barr virus promoters examined. Immunohistochemistry suggested activation of a previously silent viral antigen expression in one instance. Conclusion: Pharmacologic reversal of dense CpG methylation in tumor tissue can be achieved in patients.

UR - http://www.scopus.com/inward/record.url?scp=2342570310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342570310&partnerID=8YFLogxK

U2 - 10.1200/JCO.2004.04.185

DO - 10.1200/JCO.2004.04.185

M3 - Article

C2 - 15007085

AN - SCOPUS:2342570310

VL - 22

SP - 1373

EP - 1381

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -